Drug Type Small molecule drug |
Synonyms 3V7GQ1260K (UNII code), G-154578, G154578 + [4] |
Target |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H23N5O2 |
InChIKeyMPYACSQFXVMWNO-UHFFFAOYSA-N |
CAS Registry1206163-45-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Plaque psoriasis | Phase 2 | DE | 01 Mar 2013 | |
Plaque psoriasis | Phase 2 | GB | 01 Mar 2013 | |
Systemic Lupus Erythematosus | Phase 2 | AR | 01 Mar 2013 | |
Systemic Lupus Erythematosus | Phase 2 | CL | 01 Mar 2013 | |
Systemic Lupus Erythematosus | Phase 2 | CZ | 01 Mar 2013 | |
Systemic Lupus Erythematosus | Phase 2 | EE | 01 Mar 2013 | |
Systemic Lupus Erythematosus | Phase 2 | FR | 01 Mar 2013 | |
Systemic Lupus Erythematosus | Phase 2 | DE | 01 Mar 2013 | |
Systemic Lupus Erythematosus | Phase 2 | GR | 01 Mar 2013 | |
Systemic Lupus Erythematosus | Phase 2 | HK | 01 Mar 2013 |
Phase 2 | 68 | Placebo | mbwrjvrsqo(jfvwhnkspn) = jbeblwkohi jlgfgnqdeh (sqswchvxdb, wvhbipletp - mbymffdwak) View more | - | 03 Aug 2017 | ||
Phase 2 | 50 | zddloefhia(keutjspqvv) = Shortly thereafter, significant safety data were identified, including elevated liver enzymes in six patients (one confirmed and one suspected case of Drug Reaction with Eosinophilia and Systemic Symptoms), leading to immediate dosing cessation. xgefriueue (xiwhyxesay ) | Negative | 01 Nov 2016 | |||
Placebo |